Armistice Capital, LLC Brooklyn Immuno Therapeutics, Inc. Call Options Transaction History

Armistice Capital, LLC

  • $6.02 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding BTX

# of Institutions
1
Shares Held
1.21M
Call Options Held
0
Put Options Held
0
View Full List

About Brooklyn ImmunoTherapeutics, Inc.

BTX Quotes by TradingView
  • Ticker BTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,825,700
  • Description
  • Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...
More about BTX
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email